ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1246

Practices of Hydroxychloroquine Dosing Based on the American Association of Ophthalmology (AAO) 2016 Recommendations: A Single Center Experience

Anthony Ocon1, Muhammad Saad Shaukat2, Vivek Mehta3, Mohamed Tageldin1, David Morales4, Ernesto Acosta4, Jessica Calderone4, Marilyn Humantla4 and Ruben Peredo1, 1Medicine, Albany Medical Center, Albany, NY, 2Albany Medical Center, Albany, NY, 3Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, NY, 4Medicine, Albany Medical College, Albany, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Hydroxychloroquine and quality measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Measures and Measurement of Healthcare Quality Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

In March 2016, the AAO updated antimalarial medication screening recommendations for retinopathy prevention, with a recommended dose of hydroxychloroquine (HCQ) ≤5.0 mg/kg total body weight (TBW) as compared to ≤6.5 mg/kg ideal body weight (IBW) previously. To assess guideline implementation at the two-year mark, we compared HCQ dosing before the March 2016 update and at March 2018. We also assessed whether there was adherence to screening eye exams and evidence of retinal toxicity.

Methods:

We performed a retrospective chart review of patients on HCQ at Albany Medical Center between March 2009 through March 2018. HCQ doses based on TBW and IBW prior to the recommendation updates on March 2016 were compared to TBW-based dosing at March 2018 post-guidelines. We assessed frequency of eye examinations and evidence of retinal toxicity.

Results:

Of 248 charts reviewed, 178 were excluded due to insufficient follow-up or insufficient data for paired analysis between 3/2016 and 3/2018. 70 subjects were analyzed; 64 were female. The mean age was 42.9-years-old (95% CI 39.2-46.6). Mean duration of HCQ therapy at 3/2018 was 62.2 months (95% CI 52.4-71.9). TBW did not change between initiation of HCQ (79.5 kg, 95% CI 74.0-85.2), at 3/2016 (83.0 kg, 95% CI 77.2-88.7), or at 3/2018 (82.9 kg, 95% CI 77.0-88.8) (p=0.64). TBW-based dosage was significantly less at 3/2018 (3.9 mg/kg, 95% CI 3.6-4.2) than TBW-based at 3/2016 (4.3 mg/kg, 95% CI 4.0-4.7) (p<0.03). The TBW-based dosage was significantly less at 3/2018 (3.9 mg/kg, 95% CI 3.6-4.2) than IBW-based dosage at 3/2016 (5.8 mg/kg, 95% CI 5.4-6.2) (p<0.001). At 3/2016, 34 subjects (49%) were dosed at >6.5 mg/kg IBW (mean 7.4 mg/kg, 95% CI 7.1-7.6) and 7 subjects (10%) at >6.5 mg/kg TBW (mean 7.6 mg/kg, 95% CI 7.2-8.1). At 3/2018, 6 subjects (9%) were dosed at >5.5 mg/kg TBW (mean 6.2 mg/kg, 95% CI 5.4-6.9). Comparing the overdosed groups, the number of subjects and the TBW dosage of HCQ at 3/2018 were less than the IBW dosage of HCQ prior to 3/2016 (p<0.001). 34 of 70 (49%) patients had documented retinal exams either annually or biannually. Of the 34 IBW-overdosed at 3/2016, 30 (88%) were appropriately dosed based on TBW by 3/2018. 13 of 34 (38%) and 4 of 7 (57%) overdosed subjects based on IBW and TBW dose at 3/2016, respectfully, did not have eye exams. 4 of 7 (57%) overdosed based on TBW at 3/2018 did not have eye exams. One incidence of retinal toxicity was found and was overdosed (7.5 mg/kg) based on the IBW at 3/2016.

Conclusion:

After the AAO 2016 recommendations, dosing of HCQ decreased based on the change from IBW to TBW. The majority of patients with prior overdosing were re-dosed appropriately by 3/2018.The number of subjects overdosed on HCQ declined at two-year follow-up. Closer retinal exam follow-up is needed to improve screening and prevent toxicity. Overall, the proportion of patients at-risk based on dosage was reduced.


Disclosure: A. Ocon, None; M. Saad Shaukat, None; V. Mehta, None; M. Tageldin, None; D. Morales, None; E. Acosta, None; J. Calderone, None; M. Humantla, None; R. Peredo, None.

To cite this abstract in AMA style:

Ocon A, Saad Shaukat M, Mehta V, Tageldin M, Morales D, Acosta E, Calderone J, Humantla M, Peredo R. Practices of Hydroxychloroquine Dosing Based on the American Association of Ophthalmology (AAO) 2016 Recommendations: A Single Center Experience [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/practices-of-hydroxychloroquine-dosing-based-on-the-american-association-of-ophthalmology-aao-2016-recommendations-a-single-center-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/practices-of-hydroxychloroquine-dosing-based-on-the-american-association-of-ophthalmology-aao-2016-recommendations-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology